Download PDF
Interventionelle Radiologie Scan 2014; 02(04): 321-345
DOI: 10.1055/s-0034-1390835
Fortbildung
© Georg Thieme Verlag KG Stuttgart · New York

90Y-Radioembolisation – Evidenz bei hepatozellulärem und kolorektalem Karzinom

Max Seidensticker
,
Ricarda Seidensticker
Further Information

Publication History

Publication Date:
27 November 2014 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die RE mit Yttrium 90 Mikrosphären hat sich als wertvolle lokoregionäre Therapie in der individuellen Behandlung einzelner Stadien des HCC und des hepatisch metastasierten CRC etabliert und füllt häufig therapeutische Lücken anderer lokaler Therapien, wobei die Evidenzlage teilweise noch zu schwach ist, als dass die RE Einzug in die Leitlinien gefunden hat. Aufgrund von laufenden prospektiven Studien ist hier jedoch in naher Zukunft ein Wandel zu erwarten. Bis dahin sollte die Indikation zur RE primär durch einen interdiszplinären Tumorboardbeschluss gestellt werden und – wenn möglich – in einem Studienrahmen durchgeführt werden.

 

  • Literatur

  • 1 Campbell AM, Bailey IH, Burton MA. Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 2001; 46: 487-498
    CrossrefGoogle Scholar
  • 2 Kennedy AS, Nutting C, Coldwell D. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004; 60: 1552-1563
    CrossrefGoogle Scholar
  • 3 Crissien AM, Frenette C. Current management of hepatocellular carcinoma. Gastroenterol Hepatol (NY) 2014; 10: 153-161
    Google Scholar
  • 4 Ba SsalamahA, Grünberger T, Hoffmann M. Diagnose, Stadieneinteilung und Behandlung des hepatozellulären Karzinoms (interdisziplinär). Wien: Comprehensive Cancer Center Vienna; 2012
    Google Scholar
  • 5 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022
    CrossrefPubMedGoogle Scholar
  • 6 Llovet JM, Di Bisceglie AM, Bruix J. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711
    CrossrefGoogle Scholar
  • 7 Rahman A, Assifi MM, Pedroso FE. Is resection equivalent to transplantation for early cirrhotic patients with hepatocellular carcinoma? J Gastrointest Surg. A meta-analysis 2012; 16: 1897-1909
    Google Scholar
  • 8 Rampone B, Schiavone B, Martino A. Current management strategy of hepatocellular carcinoma. World J Gastroenterol 2009; 15: 3210-3216
    CrossrefGoogle Scholar
  • 9 Cabibbo G, Maida M, Genco C. Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response. PLoS One 2013; 8: e70016
    CrossrefGoogle Scholar
  • 10 Cucchetti A, Piscaglia F, Cescon M. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol 2013; 59: 300-307
    CrossrefPubMedGoogle Scholar
  • 11 Wang Y, Luo Q, Li Y. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas: a meta-analysis of randomized and nonrandomized controlled trials. PLoS One 2014; 9: e84484
    CrossrefGoogle Scholar
  • 12 Cho YK, Rhim H, Noh S. Radiofrequency ablation versus surgical resection as primary treatment of hepatocellular carcinoma meeting the Milan criteria: a systematic review. J Gastroenterol Hepatol 2011; 26: 1354-1360
    CrossrefPubMedGoogle Scholar
  • 13 Mazzaferro V, Regalia E, Doci R. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699
    CrossrefGoogle Scholar
  • 14 Yao FY, Xiao L, Bass NM. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007; 7: 2587-2596
    CrossrefPubMedGoogle Scholar
  • 15 Llovet JM, Ricci S, Mazzaferro V. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
    CrossrefPubMedGoogle Scholar
  • 16 Pinter M, Sieghart W, Graziadei I. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009; 14: 70-76
    CrossrefGoogle Scholar
  • 17 Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-442
    CrossrefGoogle Scholar
  • 18 Lammer J, Malagari K, Vogl T. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52
    CrossrefGoogle Scholar
  • 19 Vogl TJ, Lammer J, Lencioni R. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol 2011; 197: W562-W570
    CrossrefGoogle Scholar
  • 20 Llovet JM, Real MI, Montana X. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739
    CrossrefGoogle Scholar
  • 21 Lo CM, Ngan H, Tso WK. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171
    CrossrefGoogle Scholar
  • 22 Hu HT, Kim JH, Lee LS. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort. J Vasc Interv Radiol 2011; 22: 917-923
    CrossrefPubMedGoogle Scholar
  • 23 Burrel M, Reig M, Forner A. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol 2012; 56: 1330-1335
    CrossrefGoogle Scholar
  • 24 Chen CH, Hu FC, Huang GT. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method – analysis of 2010 Taiwanese patients. Eur J Cancer 2009; 45: 1630-1639
    CrossrefGoogle Scholar
  • 25 Lewandowski RJ, Mulcahy MF, Kulik LM. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 2010; 255: 955-965
    CrossrefGoogle Scholar
  • 26 Wang JH, Changchien CS, Hu TH. The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma – survival analysis of 3892 patients. Eur J Cancer 2008; 44: 1000-1006
    CrossrefGoogle Scholar
  • 27 Sangro B, Carpanese L, Cianni R. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011; 54: 868-878
    CrossrefGoogle Scholar
  • 28 Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011; CD004787
    Google Scholar
  • 29 Forner A, Llovet JM, Bruix J. Chemoembolization for intermediate HCC: Is there proof of survival benefit?. J Hepatol 2012; 56: 984-986
    CrossrefGoogle Scholar
  • 30 Akamatsu M, Yoshida H, Obi S. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. Liver Int 2004; 24: 625-629
    CrossrefGoogle Scholar
  • 31 Doffoel M, Bonnetain F, Bouche O. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Federation Francophone de Cancerologie Digestive 9402). Eur J Cancer 2008; 44: 528-538
    CrossrefGoogle Scholar
  • 32 Pelletier G, Roche A, Ink O. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11: 181-184
    CrossrefGoogle Scholar
  • 33 Hilgard P, Hamami M, Fouly AE. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010; 52: 1741-1749
    CrossrefGoogle Scholar
  • 34 Salem R, Lewandowski RJ, Mulcahy MF. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64
    CrossrefGoogle Scholar
  • 35 Iñarrairaegui M, Thurston KG, Bilbao JI. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010; 21: 1205-1212
    CrossrefGoogle Scholar
  • 36 D’Avola D, Lnarrairaegui M, Bilbao JI. A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. Hepatogastroenterology 2009; 56: 1683-1688
    Google Scholar
  • 37 Salem R, Lewandowski RJ, Kulik L. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140: 497-507 e492
    CrossrefGoogle Scholar
  • 38 Lewandowski RJ, Kulik LM, Riaz A. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009; 9: 1920-1928
    CrossrefPubMedGoogle Scholar
  • 39 Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-781
    CrossrefGoogle Scholar
  • 40 Society AC. Colorectal cancer facts & figures 2011–2013. Atlanta: American Cancer Society; 2011
    Google Scholar
  • 41 Andre T, Boni C, Mounedji-Boudiaf L. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351
    CrossrefGoogle Scholar
  • 42 Manfredi S, Lepage C, Hatem C. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006; 244: 254-259
    CrossrefPubMedGoogle Scholar
  • 43 Stangl R, Altendorf-Hofmann A, Charnley RM. Factors influencing the natural history of colorectal liver metastases. Lancet 1994; 343: 1405-1410
    CrossrefGoogle Scholar
  • 44 Bengtsson G, Carlsson G, Hafstrom L. Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 1981; 141: 586-589
    CrossrefGoogle Scholar
  • 45 Gray BN. Colorectal cancer: the natural history of disseminated disease – a review. Aust N Z J Surg 1980; 50: 643-646
    CrossrefGoogle Scholar
  • 46 Fong Y, Fortner J, Sun RL. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318 ; discussion 318–321
    CrossrefGoogle Scholar
  • 47 Khatri VP, Chee KG, Petrelli NJ. Modern multimodality approach to hepatic colorectal metastases: solutions and controversies. Surg Oncol 2007; 16: 71-83
    CrossrefGoogle Scholar
  • 48 Nordlinger B, Guiguet M, Vaillant JC. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77: 1254-1262
    CrossrefGoogle Scholar
  • 49 Nordlinger B, Sorbye H, Glimelius B. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016
    CrossrefGoogle Scholar
  • 50 Welsh FK, Tekkis PP, O’Rourke T. Quantification of risk of a positive (R1) resection margin following hepatic resection for metastatic colorectal cancer: an aid to clinical decision-making. Surg Oncol 2008; 17: 3-13
    CrossrefGoogle Scholar
  • 51 Scheele J, Stangl R, Schmidt K. Recurrent tumor after R0 resection of colorectal liver metastases. Incidence, resectability and prognosis. Chirurg 1995; 66: 965-973
    Google Scholar
  • 52 Hochster HS, Hart LL, Ramanathan RK. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26: 3523-3529
    CrossrefGoogle Scholar
  • 53 Van Cutsem E, Kohne CH, Lang I. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-2019
    CrossrefPubMedGoogle Scholar
  • 54 Van Cutsem E, Tabernero J, Lakomy R. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30: 3499-3506
    CrossrefGoogle Scholar
  • 55 Grothey A, Van Cutsem E, Sobrero A. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303-312
    CrossrefGoogle Scholar
  • 56 Van Cutsem E, Kohne CH, Hitre E. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417
    CrossrefGoogle Scholar
  • 57 Douillard JY, Oliner KS, Siena S. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034
    CrossrefPubMedGoogle Scholar
  • 58 Adam R, Delvart V, Pascal G. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-657 ; discussion 657–648
    Google Scholar
  • 59 Adam R, Wicherts DA, de Haas RJ. Patients with initially unresectable colorectal liver metastases: Is there a possibility of cure?. J Clin Oncol 2009; 27: 1829-1835
    CrossrefGoogle Scholar
  • 60 Folprecht G, Gruenberger T, Bechstein WO. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47
    CrossrefGoogle Scholar
  • 61 Giacchetti S, Itzhaki M, Gruia G. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663-669
    CrossrefGoogle Scholar
  • 62 Folprecht G, Grothey A, Alberts S. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16: 1311-1319
    CrossrefGoogle Scholar
  • 63 Falcone A, Ricci S, Brunetti I. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676
    CrossrefGoogle Scholar
  • 64 Fornaro L, Lonardi S, Masi G. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol 2013; 24: 2062-2067
    CrossrefGoogle Scholar
  • 65 Bridgewater J, Adam R, Chau I. Updated efficacy/safety findings from a randomized, phase 2 study of bevacizumab plus mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer (OLIVIA study). European Cancer Congress 2013; Abstract 2159
    Google Scholar
  • 66 Falcone A, Cremolini C, Masi G. FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group. Journal of Clinical Oncology 2013; ASCO Annual Meeting Abstracts; Abstract 3505
    Google Scholar
  • 67 Schmoll HJ, Van Cutsem E, Stein A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479-2516
    CrossrefGoogle Scholar
  • 68 Hendlisz A, Van den Eynde M, Peeters M. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010; 28: 3687-3694
    CrossrefGoogle Scholar
  • 69 Seidensticker R, Denecke T, Kraus P. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol 2012; 35: 1066-1073
    CrossrefGoogle Scholar
  • 70 Bester L, Meteling B, Pocock N. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol 2012; 23: 96-105
    CrossrefGoogle Scholar
  • 71 Cosimelli M, Golfieri R, Cagol PP. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 2010; 103: 324-331
    CrossrefGoogle Scholar
  • 72 Gray B, Van Hazel G, Hope M. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001; 12: 1711-1720
    CrossrefGoogle Scholar
  • 73 Van Hazel G, Blackwell A, Anderson J. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004; 88: 78-85
    CrossrefGoogle Scholar
  • 74 Sharma RA, Van Hazel GA, Morgan B. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 2007; 25: 1099-1106
    CrossrefGoogle Scholar
  • 75 Gulec SA, Pennington K, Wheeler J. Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial. Am J Clin Oncol 2013; 36: 455-460
    CrossrefGoogle Scholar
  • 76 Seidensticker R, Seidensticker M, Damm R. Hepatic toxicity after radioembolization of the liver Uusing Y-90-microspheres: sequential lobar versus whole liver approach. Cardiovasc Intervent Radiol 2012; 35: 1109-1118
    CrossrefGoogle Scholar
  • 77 Mansmann U, Sartorius U, Laubender R. Quantitative analysis of the impact of deepness of response on post-progression survival time following first-line treatment in patients with mCRC. Journal of Clinical Oncology 2013; ASCO Annual Meeting Abstracts; Abstract 3630
    Google Scholar
  • 78 Kosmider S, Tan TH, Yip D. Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer. J Vasc Interv Radiol 2011; 22: 780-786
    CrossrefGoogle Scholar
  • 79 Kennedy AS, Ball D, Cohen S. Multicenter comparison of safety and efficacy of yttrium-90 resin microsperes in elderly (> 70 years) and younger patients with unresectable liver-dominant metastastic colorectal cancer. Cardiovascular and Interventional Radiology Society of Europe Meeting. 2013 Abstract 3109.5
    Google Scholar
  • 80 Sangro B, Gil-Alzugaray B, Rodriguez J. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 2008; 112: 1538-1546
    CrossrefGoogle Scholar
  • 81 Farthing MJ, Clark ML, Sloane JP. Liver disease after bone marrow transplantation. Gut 1982; 23: 465-474
    CrossrefGoogle Scholar
  • 82 Lawrence TS, Robertson JM, Anscher MS. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995; 31: 1237-1248
    CrossrefGoogle Scholar
  • 83 McDonald GB, Sharma P, Matthews DE. The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation. Transplantation 1985; 39: 603-608
    CrossrefGoogle Scholar
  • 84 Forrest DL, Thompson K, Dorcas VG. Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study. Bone Marrow Transplant 2003; 31: 1143-1149
    CrossrefGoogle Scholar
  • 85 McDonald GB, Sharma P, Matthews DE. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122
    CrossrefGoogle Scholar
  • 86 Shulman HM, Hinterberger W. Hepatic veno-occlusive disease – liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 197-214
    Google Scholar
  • 87 Gil-Alzugaray B, Chopitea A, Inarrairaegui M. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 2013; 57: 1078-1087
    CrossrefGoogle Scholar
  • 88 Ingold JA, Reed GB, Kaplan HS. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 1965; 93: 200-208
    Google Scholar
  • 89 Kim TH, Panahon AM, Friedman M. Acute transient radiation hepatitis following whole abdominal irradiation. Clin Radiol 1976; 27: 449-454
    CrossrefGoogle Scholar
  • 90 Reed Jr GB, Cox Jr AJ. The human liver after radiation injury. A form of veno-occlusive disease. Am J Pathol 1966; 48: 597-611
    Google Scholar
  • 91 Fajardo LF, Berthrong M. Radiation injury in surgical pathology. Part I. Am J Surg Pathol 1978; 2: 159-199
    Google Scholar
  • 92 Fajardo LF, Colby TV. Pathogenesis of veno-occlusive liver disease after radiation. Arch Pathol Lab Med 1980; 104: 584-588
    Google Scholar
  • 93 Lewin K, Millis RR. Human radiation hepatitis. A morphologic study with emphasis on the late changes. Arch Pathol 1973; 96: 21-26
    Google Scholar
  • 94 Rubin P. The Franz Buschke lecture: late effects of chemotherapy and radiation therapy: a new hypothesis. Int J Radiat Oncol Biol Phys 1984; 10: 5-34
    Google Scholar
  • 95 Sempoux C, Horsmans Y, Geubel A. Severe radiation-induced liver disease following localized radiation therapy for biliopancreatic carcinoma: activation of hepatic stellate cells as an early event. Hepatology 1997; 26: 128-134
    CrossrefGoogle Scholar
  • 96 Geraci JP, Mariano MS. Radiation hepatology of the rat: parenchymal and nonparenchymal cell injury. Radiation Res 1993; 136: 205-213
    CrossrefGoogle Scholar
  • 97 Jirtle RL, Michalopoulos G, McLain JR. Transplantation system for determining the clonogenic survival of parenchymal hepatocytes exposed to ionizing radiation. Cancer Res 1981; 41: 3512-3518
    Google Scholar
  • 98 Johnson LK, Longenecker JP, Fajardo LF. Differential radiation response of cultured endothelial cells and smooth myocytes. Anal Quant Cytol 1982; 4: 188-198
    Google Scholar
  • 99 Kennedy AS, McNeillie P, Dezarn WA. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 2009; 74: 1494-1500
    CrossrefGoogle Scholar